Member Info for Uncanny

Ok Mother Teresa, l better call the Samaritans then! 😂😂😂

Please Rat, be my guest and post as often and as you feel fit as nobody takes a blind bit of notice. Just seen that you have posted more than anyone else on here in the last 30 days, so maybe you are bordering on obsession as a non-shareholder, not short, not looking to buy nor sell.... quite strange IMHO unless you cant let go over a previous loss you have had to write off?

Anyway each to their own and I will continue to build my stake as I feel fit

Yet more scaremongering from you (and if you don't mind me saying, taken to a different level now and in bad taste as per your last post), as we get closer and closer to monetisation with the rewards potentially being mind blowing for those with the tenacity at this stage now with the right person at the helm with the right IP, right strategy and in right place at the right time.

GLA NAI DYOR IMHO

😂😂😂

Oh dear Rat, my word you seem very bitter and agitated on this BB with VAL, maybe have a lie down or go out for a walk and relax my friend. 👍

And following on Rat, who in their right mind would want to trash a company that is striving to find solutions for unmet medial needs, particulalry cancer?

Sadly Rat., I don't have 6% in SHEL, AZN or any of my other portfolio holdings by value but all relative my dear boy!

All relative to a balanced portfolio my dear Rat!

I sleep very well thank you. LOL

Fair enough Rat, but as I own 6.1% of the company so I feel I have good cause and reason to follow the stock at it s posts I have invested in!

Slight difference to a non-shareholder, like Porky who just bates and other trolls like yourself I believe with also no shareholding with more post than me!

Rat = 23 post in the last 30 days, 🤣🤣🤣

A open forum for anyone to comment, PMSL: perhaps I am wrong, but 5 posts by you in 24 hours I would say is a little on the excessive side for a non-shareholder?

Just for you Porky, what you are referring to with regards ME attending global forums in front of the worlds largest oncology pharma's to promote CLX, we call in the business world marketing, so just for your benefit to help :

"the activity, set of institutions, and processes for creating, communicating, delivering, and exchanging offerings that have value for customers, clients,

partners, and society at large"

Rat, yes we can call her as long as you promise to jump in the hole after its dug!

Porky so naïve, a Zoom call, its not a middle management admin teams meeting! Maybe you should put your Robin Hood mask on 🤣🤣🤣

Its Monday morning and your posting now, over the weekend, last night and you don't hold any shares... quite bizarre behaviour.

😂😂😂😂

It seems we have the Viera Porky show or Pink Nick as someone previously affectionately called them / him on here.

Some seem to know as much about history as they do about biotech as Dick Turpin wore a mask and Robin Hood was famed from taking from the rich to give to the poor which is basically an inverse of being a trader and scaremongering small investors to sell l guess?

I’m sure ME made some valuable contacts which l presume we will hear about in the weeks to come by RNS.

Anyway, just to reiterate do it doesn’t get drowned out by the deramping desperation:

“ValiRx is in discussions with several potential partners to progress Cytolytix, including a major pharmaceutical company”. (RNS 1/9/25)“

GLA DYOR NAI IMHO

Nice to a different team at the top!

I would argue that is definitely showing commercial nous by ME:

“ValiRx is in discussions with several potential partners to progress Cytolytix, including a major pharmaceutical company”. (RNS 1/9/25)“

Sorry, here is the link - we don’t know what NDA’s and CDA’s VAL has in place for CLX nor 201 for that matter!

https://dealforma.com/biopharma-therapeutics-and-platforms-2024-q2-2025/

For oncology M&A in the small-cap bio space from 2024 through Q2 2025, the average upfront payment was around $1 billion, with a median of about $403 million. While averages can be skewed by large deals, these figures indicate a significant but varied valuation landscape for smaller oncology companies looking to be acquired.

Https://discover-pharma.com/inaphaea-biolabs-boosts-precision-oncology-with-new-partnerships-advanced-tumour-models-and-digital-patient-avatars/

😂😂😂

Who said they build a business around tax credits?

Anyway, nothing for you to worry about Porky as you don't have a holding here, in fact the only thing you hold is sour grapes with regards to Valirx I believe? From your past investment history (DDDD etc) I really don't think you are in a very good position to be preaching do you and you are not particularly showing savvy investment prowess when everyone knows most bio's and related rely on fundraises to the point when they start to monetise their IP like APTA last month as an example and many more to cite.... VAL are now finally on the cusp of greatness from a sad and chequered history I agree.

Just for the record, ME clearly stated previously that all the redundancies were done in June (nothing more to pay) and how on earth do you market your products if you don't stick you face in an audience of reps from the largest multi-billion dollar pharma companies in the world looking for new opportunities to partner with bio small caps?

Porky, when you get your PhD and evaluating Oncology IP and find a commercial behemoth like CLX which is on the brink of being IND ready for early partnering (not years like you say) and in talks with potential partners now including a major pharma as per recent RNS, and ....... like our CEO having a track record of spinning out a microcap like Volition in to £250 million market cap company, then and only then will I listen to what you have t say, until then, please stick to the day job..... there's a good fellow.

GLA IMHO NAI DYOR

We don’t know what the tax credits are in the current quarter, income from the lab, where talks are on 201 and as we all know from the second to last RNS is:

"ValiRx are in discussions with several potential partners to progress Cytolytix, including a major pharmaceutical company and further non-dilutive funding options with our academic partners."

Think you guys are missing the R&D tax credits and the fact that most of the cost savings didn’t kick in H1. All clearly stated in the report….

To be honest, not really bothered about the competitors as a shareholder. I am more interested about what Valirx are doing and I’m sure ME is juggling hopefully quite a few options which I am sure will come to light in the days and weeks to come.

DYOR NAI IMHO GLA

I don't think people will understand the magnitude of this development and presume ME will elaborate upon his return from all the presentations this week.

Of the 250 hits, 50 have known activity in cancer - VAL are taking the top 10 starting with Ovarian cancer.

The cost and speed of doing this is mind boggling as compared to some years ago, so as well as revenue there are tremendous costs savings and speedier IP pipeline growth than the old university tie ups, albeit these are still ongoing, plus quicker monetisation of assets.